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The left panels demonstrate heterogeneity of CD8 T cell densities in 200 genital tract micro regions in our 
mathematical model. Each region is intended to approximate a 5 mm diameter of tissue. The right panels 
demonstrate the reproductive number, which is inversely correlated with CD8+ T cell density. There is no potential for 
virus to spread extensively in grey or black regions, whereas green regions are not immunologically protected and 
virus has the potential to expand more extensively leading to lesions. The top two panels represent a simulated 
patient on no drug. The bottom two panels demonstrate a simulated patient on high dose pritelivir (75mg daily). 
While, there is an equivalent spatial distribution of CD8 T cell densities across the genital tract, the overall growth 
potential for virus is lower on high dose treatment: a higher percentage of regions are grey or black meaning that 
HSV reactivation would result in rapid viral elimination. 
 
Image provided by Dr. Joshua Schiffer. 
An often unappreciated facet of developing new therapeutics is the design and execution of clinical 
trials. Recently, predictive therapeutic biomarkers have become commonplace for trial design. By 
understanding the molecular drivers of disease researchers have developed drugs that target these 
molecular pathologies. Drugs like vemurafenib (for mutant BRAF in melanoma) are only beneficial to 
patients affected by specific genetic and molecular lesions. Identifying and enriching the clinical trial 
population for likely 'responders' results in a clear representation of drug efficacy. However, even 
with the best patient groups doctors must still identify optimal doses for a trial to demonstrate 
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efficacy. Often these are estimated from results of human cultured cells and mouse models of 
disease. Doctors must understand the lifespan of the compound in the human body, but also the 
drug concentration required to achieve the desired activity. When doses are too high they can cause 
unnecessary adverse effects, when doses are too low therapies are not efficacious. Dr. Joshua 
Schiffer and other Fred Hutch researchers in the Clinical Research and Vaccine and Infectious 
Disease Divisions are using mathematical models to identify optimum patient dosing for antiviral 
therapies. In a recent Science Translational Medicine article, researchers developed a mathematical 
model of herpes simplex virus (HSV2) suppression using the novel helicase inhibitor, pritelivir. 
The model consists of three major sets of equations for the following: pharmacodynamics (PD), 
pharmacokinetics (PK), and viral kinetics in the absence of drug. PD equations represent the 
concentration dependent inhibition of pritelivir on HSV2 shedding, while PK equations model the 
distribution and serum lifespan of pritelivir. The FDA requires PK and PD data for licensure of all new 
therapeutics; however, in modeling and understanding HSV2 suppression, researchers found these 
equations alone could not explain results seen in clinical trials. "We identify that standard 
pharmacodynamics models do not accurately capture the true potency of antiviral drugs. To 
compute this potency in a dose response fashion requires synthesizing these models with equations 
that capture the natural features of infection," said Dr. Schiffer. A key component to modeling HSV2 
infection was to include equations representing the infectious cycle of the virus. In an infected 
individual, a herpes outbreak occurs when virus is released from a neuronal pool and infects the 
genital tract. As virus incubates in this initial site of genital infection, it can then spread locally 
ultimately becoming a lesion. Researchers modeled this using 200 'micro regions' where virus could 
spread depending on the location and T cell activity of each micro region.  
To validate this model, researchers compared its predictions to patient data from an in-depth phase 
II trial using pritelivir. In that trial patients were placed on four different pritelivir doses, then patients 
swabbed commonly infected areas every day for the one month trial. From these samples 
researchers measured HSV copy numbers and found that higher daily doses of pritelivir decreased 
viral shedding. The mathematical model was used to simulate over 100 trials that consistently 
predicted equivalent shedding rates to real patients at all four doses. The model also demonstrated 
that pritelivir decreased HSV shedding rates by indirectly decreasing viral cell-to-cell transmission. 
Upon a new outbreak there is a lag in the immune response required to clear the virus, if 
neighboring cells are infected during this lag time they will still be cleared, but if a spatially distant 
seeding occurs this will prolong the episode length. Thus by decreasing cell-to-cell transmission 
overall, pritelivir dramatically reduces these secondary ulcers and overall outbreak length. 
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In generating this mathematical model researchers also identified important new measures for 
choosing doses in clinical trials. Most doses are estimated from EC50 measures established with 
cultured human cells that may not fully represent in vivo activity. Researchers identified an 'in vivo 
EC50' by testing many EC50 values (drug concentration in serum) in their model ranging from 0-100 
ng/mL and comparing the results to the patient shedding numbers. It was found that pritelivir doses 
from 50-70 ng/mL best matched patient data, importantly these values range from 2-15 fold higher 
than in vitro studies. The model also revealed that pritelivir levels are very stable in patients, which 
translates to understanding patient response even with missed doses, "a surprising finding was that 
total cumulative weekly dose is highly predictive of shedding rate in a clinical trial population. 
Therefore, if we knew the number of missed doses, we could extrapolate the predictive shedding 
rate" said Dr. Schiffer. 
While this model is specific to HSV2 and pritelivir, this approach can be adapted to other infectious 
diseases, as long as the viral kinetics are well understood. A model specific to one disease and drug 
combination would function very much like a therapeutic biomarker, and could increase the 
efficiency of clinical trials. "I am hopeful that our approach will allow the field to more accurately 
assess drug potency in vivo and therefore select dosing regimens more strategically. This could 
potentially lower expenditures on drug trials and also increase the likelihood of demonstrating 
therapeutic efficacy" said Dr. Schiffer. 
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